Medications for Cervical Cancer
Other names: Cancer, Cervix
Drugs used to treat Cervical Cancer
The following list of medications are in some way related to or used in the treatment of this condition.
Drug name | Rating | Reviews | Activity ? | Rx/OTC | Pregnancy | CSA | Alcohol |
---|---|---|---|---|---|---|---|
cisplatin | Rate | Add review | Rx | ||||
Generic name: cisplatin systemic Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Avastin | 10 | 2 reviews | Rx | ||||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
methotrexate Off-label | Rate | Add review | Rx | ||||
Generic name: methotrexate systemic Drug class: antimetabolites, antirheumatics, antipsoriatics, other immunosuppressants For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information Off-label: Yes |
|||||||
Keytruda | 1.0 | 3 reviews | Rx | ||||
Generic name: pembrolizumab systemic Drug class: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
pembrolizumab | 1.0 | 3 reviews | Rx | ||||
Generic name: pembrolizumab systemic Brand name: Keytruda Drug class: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
carboplatin | Rate | Add review | Rx | ||||
Generic name: carboplatin systemic Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Hycamtin | Rate | Add review | Rx | ||||
Generic name: topotecan systemic Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
hydroxyurea Off-label | Rate | Add review | Rx | ||||
Generic name: hydroxyurea systemic Drug class: antimetabolites For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information Off-label: Yes |
|||||||
Ifex | Rate | Add review | Rx | ||||
Generic name: ifosfamide systemic Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
bevacizumab | 9.5 | 3 reviews | Rx | ||||
Generic name: bevacizumab systemic Brand names: Avastin, Mvasi, Zirabev, Alymsys, Vegzelma …show all Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
Mvasi | Rate | Add review | Rx | ||||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
topotecan | Rate | Add review | Rx | ||||
Generic name: topotecan systemic Brand name: Hycamtin Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
fluorouracil | Rate | Add review | Rx | ||||
Generic name: fluorouracil systemic Drug class: antimetabolites For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
ifosfamide | Rate | Add review | Rx | ||||
Generic name: ifosfamide systemic Brand name: Ifex Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
cyclophosphamide Off-label | Rate | Add review | Rx | ||||
Generic name: cyclophosphamide systemic Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information Off-label: Yes |
|||||||
Zirabev | Rate | Add review | Rx | ||||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Alymsys | Rate | Add review | Rx | ||||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
tisotumab vedotin | Rate | Add review | Rx | ||||
Generic name: tisotumab vedotin systemic Brand name: Tivdak Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
Tivdak | Rate | Add review | Rx | ||||
Generic name: tisotumab vedotin systemic Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Vegzelma | Rate | Add review | Rx | ||||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Frequently asked questions
- Why give Taxol (Paxel) before carboplatin?
- Pembrolizumab vs. nivolumab: how do they compare?
- Does carboplatin cause neuropathy?
- What is the difference between Mvasi and Avastin?
Learn more about Cervical Cancer
Care guides
Symptoms and treatments
Legend
Rating | For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |
---|---|
Activity | Activity is based on recent site visitor activity relative to other medications in the list. |
Rx | Prescription only. |
OTC | Over-the-counter. |
Rx/OTC | Prescription or Over-the-counter. |
Off-label | This medication may not be approved by the FDA for the treatment of this condition. |
EUA | An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives. |
Expanded Access | Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. |
Pregnancy Category | |
---|---|
A | Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. |
C | Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
X | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits. |
N | FDA has not classified the drug. |
Controlled Substances Act (CSA) Schedule | |
---|---|
M | The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication. |
U | CSA Schedule is unknown. |
N | Is not subject to the Controlled Substances Act. |
1 | Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision. |
2 | Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
3 | Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
4 | Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
5 | Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Alcohol | |
---|---|
X | Interacts with Alcohol. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.